Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 14/20 | 0.49 |
| ▸ | MC4R | P32245 | 2/20 | 0.43 |
| ▸ | MC5R | P33032 | 2/20 | 0.43 |
| ▸ | MC3R | P41968 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2811764 | 0.86 | REN (0.49) | RENMC4RMC5RMC3RKDM4E | |
| SCHEMBL13132250 | 0.86 | REN (0.43) | RENMC4RMC5RMC3RCYP3A4 | |
| SCHEMBL13131519 | 0.82 | REN (0.72) | REN | |
| SCHEMBL3375031 | 0.75 | MAPT (0.48) | CYP3A4KCNH2KDM4EALDH1A1HPGD | |
| SCHEMBL13132343 | 0.75 | KMT2A (0.50) | CYP3A4KDM4EALDH1A1GAANPSR1 | |
| SCHEMBL13132483 | 0.75 | REN (0.46) | REN | |
| SCHEMBL2806187 | 0.74 | LPAR1 (0.36) | CYP3A4KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL2805304 | 0.74 | REN (0.44) | RENKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL13132246 | 0.73 | MTNR1A (0.44) | RENMC4RMC5RMC3R | |
| SCHEMBL18509018 | 0.73 | REN (0.43) | RENCYP3A4KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8975252-B2 | Morpholine derivative | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2015-03-10 | — | — | US | disclosed |
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240644-A1 | MORPHOLINE DERIVATIVE | REN, AGTR1, AGTR2 | REN 1/4885MC4R 185/4885MC5R 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.